Scarica l'app Stockscreener
2.225
3.26%
0.075
Taysha Gene Therapies Inc Borsa (TSHA) Ultime notizie
TG Therapeutics Inc (TGTX) may enjoy gains as insiders got busy in the recent days - Knox Daily
IBD 50 Biotech Stock Rises On Five-Year Data For MS Drug - Investor's Business Daily
What's Going On With TG Therapeutics Stock Wednesday? - Benzinga
TG Therapeutics (NASDAQ:TGTX) Hits New 52-Week High at $26.03 - MarketBeat
Tango Therapeutics Inc (TNGX) Stock: A Year of Stock Market Ups and Downs - The InvestChronicle
Closing Bell Recap: Taysha Gene Therapies Inc (TSHA) Ends at 2.17, Reflecting a -5.24 Downturn - The Dwinnex
Market Insights: TG Therapeutics Inc (TGTX)’s Notable Gain of 4.89, Closing at 24.89 - The Dwinnex
Ashton Thomas Private Wealth LLC Takes Position in TG Therapeutics, Inc. (NASDAQ:TGTX) - Defense World
Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Receives Average Rating of "Buy" from Brokerages - MarketBeat
Tango Therapeutics Inc [TNGX] Investment Appeal on the Rise - Knox Daily
Tango Therapeutics (NASDAQ:TNGX) Shares Down 12.4% - MarketBeat
It makes sense and dollars to buy TG Therapeutics Inc (TGTX) stock - SETE News
TG Therapeutics stock soars to 52-week high of $25.71 - Investing.com India
A new trading data show Taysha Gene Therapies Inc (TSHA) is showing positive returns. - SETE News
Implant maker Tenon Medical nearly triples its market capitalization in two days - Kursiv Media
Tenon Medical stock jumps 73% in wake of Nasdaq listing update (NASDAQ:TNON) - Seeking Alpha
Taysha Gene Therapies Inc’s results are impressive - US Post News
Tay-Sachs Disease Market to Witness Growth by 2032 | Companies - openPR
Taysha Gene Therapies announces inducement grant under Nasdaq listing rule - TipRanks
Buying Buzz: Taysha Gene Therapies Inc [TSHA] 10% Owner Manning Paul B purchases 1,333,333 shares of the company – Knox Daily - Knox Daily
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - StockTitan
Class Attys Vie To Lead Drug Co. Insider Trading Suit In Del. - Law360
Stock Surge: Taysha Gene Therapies Inc (TSHA) Closes at 2.07, Marking a 0.49 Increase/Decrease - The Dwinnex
Does Taysha Gene Therapies Inc (TSHA) offer a good opportunity for investors? - SETE News
Rett Syndrome Market Expected to Experience Major Growth - openPR
Checking in on Taysha Gene Therapies Inc (TSHA) after recent insiders movement - Knox Daily
Giant Axonal Neuropathy Market Growth to Accelerate in Forecast - openPR
Analytical Overview: Taysha Gene Therapies Inc (TSHA)’s Ratios Tell a Financial Story - The Dwinnex
A closer look at Taysha Gene Therapies Inc (TSHA)’s stock price trends - US Post News
Its Stock Has Paid Off Big Time For Taysha Gene Therapies Inc - SETE News
Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Receives $6.22 Average Price Target from Analysts - MarketBeat
TSHA (Taysha Gene Therapies) Enterprise Value : $344.05 Mil (As of Aug. 20, 2024) - GuruFocus.com
TSHA (Taysha Gene Therapies) Cash From Discontinued Investi - GuruFocus.com
Chardan Capital Equities Analysts Increase Earnings Estimates for Taysha Gene Therapies, Inc. (NASDAQ:TSHA) - MarketBeat
Chardan Capital Equities Analysts Increase Earnings Estimates for Taysha Gene Therapies, Inc. (NASDAQ:TSHA) - Defense World
Taysha Gene Therapies Second Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance
Taysha Gene Therapies (NASDAQ:TSHA) PT Lowered to $6.00 - Defense World
Cantor Fitzgerald Brokers Raise Earnings Estimates for Taysha Gene Therapies, Inc. (NASDAQ:TSHA) - Defense World
Taysha Gene Therapies, Inc. to Post FY2024 Earnings of ($0.34) Per Share, Cantor Fitzgerald Forecasts (NASDAQ:TSHA) - MarketBeat
BMO maintains Outperform on Taysha Gene By Investing.com - Investing.com Canada
Canaccord sees regulatory engagement boosting Taysha Gene stock outlook By Investing.com - Investing.com Canada
Taysha Gene Therapies (NASDAQ:TSHA) Price Target Lowered to $6.00 at Canaccord Genuity Group - MarketBeat
Taysha Gene Therapies (NASDAQ:TSHA) Posts Quarterly Earnings Results, Beats Expectations By $0.01 EPS - Defense World
Taysha Gene Therapies Second Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag - Simply Wall St
Taysha Gene Therapies (NASDAQ:TSHA) Price Target Cut to $6.00 - Defense World
Taysha Gene Therapies (NASDAQ:TSHA) Receives Buy Rating from Chardan Capital - Defense World
Taysha Gene Therapies' (TSHA) Buy Rating Reaffirmed at Chardan Capital - MarketBeat
Taysha Gene Therapies (NASDAQ:TSHA) Posts Quarterly Earnings Results, Beats Expectations By $0.01 EPS - MarketBeat
Vanguard Group Inc. Sells 278,153 Shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA) - MarketBeat
Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Q2 2024 Earnings Call Transcript - Insider Monkey
Vanguard Group Inc. Trims Stake in Taysha Gene Therapies, Inc. (NASDAQ:TSHA) - Defense World
Taysha Gene Therapies Inc (TSHA) Q2 2024 Earnings Call Transcrip - GuruFocus.com
Taysha Gene Therapies (NASDAQ:TSHA) PT Lowered to $6.00 - MarketBeat
Earnings call: Taysha Gene Therapies reports progress on Rett Syndrome trial - Investing.com
Peeling Back The Layers: Exploring Taysha Gene Therapies Through Analyst Insights - Benzinga
TSHA Stock Earnings: Taysha Gene Therapies Beats EPS, Misses Revenue for Q2 2024 - InvestorPlace
Taysha Gene Therapies, Inc. (TSHA) Q2 2024 Earnings Call Transcript - Seeking Alpha
Taysha Gene Therapies, Inc. (TSHA) Reports Q2 Loss, Lags Revenue Estimates - MSN
Taysha Gene Therapies, Inc. (TSHA) Reports Q2 Loss, Lags Revenue Estimates - Yahoo Finance
Taysha Gene Therapies Reports Second Quarter 2024 Financial Results and Provides Corporate Update - GlobeNewswire
Taysha Gene Therapies Reports Second Quarter 2024 Financial Results and Provides Corporate Update - StockTitan
Taysha Gene Therapies, Inc. (NASDAQ:TSHA) has caught the attention of institutional investors who hold a sizeable 46% stake - Yahoo Finance
Taysha Gene Therapies (TSHA) to Release Earnings on Monday - Defense World
Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Shares Sold by Price T Rowe Associates Inc. MD - Defense World
1.07%
2.16%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Capitalizzazione:
|
Volume (24 ore):